<?xml version="1.0"?>
<Articles JournalTitle="Academic Journal of Surgery">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences (TUMS)</PublisherName>
      <JournalTitle>Academic Journal of Surgery</JournalTitle>
      <Issn>2423-3218</Issn>
      <Volume>8</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2025</Year>
        <Month>12</Month>
        <Day>22</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Evaluation of the Safety of Low-Dose Topical Imiquimod Cream on Frontal Sinus Ostium Stenosis Following Endoscopic Sinus Surgery: A Pilot Clinical Trial</title>
    <FirstPage>101</FirstPage>
    <LastPage>105</LastPage>
    <AuthorList>
      <Author>
        <FirstName>elnaz</FirstName>
        <LastName>mokhtari</LastName>
        <affiliation locale="en_US">Elnaz Mokhtari, ENT Resident, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2025</Year>
        <Month>06</Month>
        <Day>04</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Introduction: Frontal sinus ostium stenosis is a common postoperative challenge in endoscopic sinus surgery, potentially leading to disease recurrence. Imiquimod is an immunomodulatory agent with anti-inflammatory and antifibrotic properties, recently gaining attention in experimental studies.
Objective: To evaluate the safety of low-dose topical imiquimod cream in reducing the rate of frontal sinus ostium stenosis following endoscopic sinus surgery.
Methods: This pilot randomized intra-patient controlled clinical trial was conducted on 20 patients with CRSwNP. Each patient underwent bilateral Draf 2a surgery. One frontal sinus was randomly assigned to receive Gelfoam impregnated with 5% imiquimod cream, with applications repeated in the second and fourth postoperative weeks. The contralateral side served as the control. Patients were assessed at week 4 and month 3 postoperatively via endoscopic and CT imaging. Endoscopic scores were based on the DIP system, and the STDR ratio was evaluated using 3D CT reconstruction. Data analysis was performed using paired t-tests and Wilcoxon tests at a significance level of 0.05.
Results: At three months post-surgery, STDR was significantly lower on the intervention side (p &lt; 0.05), indicating reduced soft tissue density and opacification. Endoscopic evaluation also showed a marked improvement in polyp and inflammation scores on the treated side. No significant differences were observed at one month. No major local or systemic adverse effects were reported.
Conclusion: Topical application of low-dose imiquimod cream after endoscopic sinus surgery may effectively reduce inflammation, discharge, polyp formation, and opacification in the frontal sinus, and may be considered a safe preventive option for ostium stenosis. Larger trials are recommended to confirm these findings</abstract>
    <web_url>https://ajs.tums.ac.ir/index.php/ajs/article/view/317</web_url>
  </Article>
</Articles>
